Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
December 2023
Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort
Arthritis Rheumatol. 2023; 75(12):2195–2206 DOI: 10.1002/art.42645
n this study, severe nonadherence to hydroxychloroquine (HCQ) was independently associated with the risk of SLE flare in the following year, early damage and 5-year mortality.
Keywords:
May 2023
Development of American College of Rheumatology Quality Measures for Systemic Lupus Erythematosus: A Modified Delphi Process with RISE Registry Data Review
Arthritis Care Res (Hoboken). 2023 doi: 10.1002/acr.25143
The first ACR quality measures for SLE selected by Bartels, et al. use a rigorous Delphi process, and include recommendations on hydroxychloroquine, glucocorticoid reduction and kidney monitoring.
November 2022
Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: A Prospective, Multinational, Longitudinal Cohort Study
Lancet Rheumatol. 2022. Epub ahead of print. doi: 10.1016/S2665-9913(22)00304-6
Lupus low disease activity state (LLDAS) significantly reduced the risk of mortality in patients with SLE.
May 2022
Major Determinants of Prolonged Remission in Systemic Lupus Erythematosus: Retrospective Study Over a 41+ Year Period
Rheumatology (Oxford). 2022 Epub ahead of print
Retrospective observational study over a 41-year period finds complete remission (CR) in SLE to be associated with Caucasian race, older age at diagnosis, absence of renal involvement and absence of antiphospholipid syndrome.
January 2022
Efficacy and Safety of Ustekinumab in Patients with Active Systemic Lupus Erythematosus: Results Through 2 Years of an Open-Label Extension in a Phase 2 Study
J Rheumatol. 2021. Epub ahead of print
Phase II data demonstrate clinical benefit in global and organ-specific SLE-activity measures with ustekinumab through 2 years with no new or unexpected safety findings.